Article Text

Download PDFPDF

Immune profiling in human breast cancer is predictive of 5- and 10-year survival.
  1. Brendon Coventry1,
  2. Michael J Weightman1,
  3. John Bradley2 and
  4. John M Skinner3
  1. Aff1 grid.416075.10000000403671221Discipline of SurgeryUniversity of Adelaide & Breast, Endocrine & Surgical Oncology Unit, Royal Adelaide Hospital Australia
  2. Aff2 grid.1014.40000000403672697Department of Clinical ImmunologyFlinders University, Flinders Medical Centre Adelaide Australia
  3. Aff3 grid.1014.40000000403672697PathologyFlinders University, Flinders Medical Centre Adelaide Australia

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Meeting abstracts


Immunotherapy for breast cancer is now being seriously considered, despite past beliefs that this cancer type was non-immunogenic. Immune profiling has been variably associated with outcome, but standard techniques have greatly limited interpretation. These studies examine immune profiling of breast cancer patients using high-sensitivity methods in relation to clinical outcome.


High-sensitivity detection and analysis methods were used to determine Immune Profiles of female human breast cancer in Tumour Infiltrating Leukocytes (TIL) in longitudinal cohort comparative outcome studies.


Immune profiles showed predominantly CD3, CD4, CD45RO TIL with low/absent IL-2a receptor expression. However, these were significantly correlated to 5- and 10-year survival times.


Immune profiling of the TIL infiltrate in human breast carcinoma using high-sensitivity detection and analysis techniques showed predominance of CD3 cells, being ab-TCR, CD4 T cells of mainly memory phenotype. Importantly, these findings were strongly predictive of 5- and 10-year survival. This indicates the real possibility that TIL infiltration in breast cancer might be open to immunological manipulation therapeutically to improve clinical outcome.